EE47 Cost-Effectiveness of Abiraterone, Enzalutamide, and Apalutamide in Metastatic Castration-Sensitive Prostate Cancer (MCSPC): A Partitioned-Survival Model
Prostate cancer is the second leading cause of death and second most common cancer among American men. Metastatic castration-sensitive prostate cancer (mCSPC) has largely been treated with androgen deprivation therapy (ADT) alone or ADT plus docetaxel for the past few decades. The emergence of antiandrogen therapies like abiraterone acetate, apalutamide, and enzalutamide in the last decade has transformed the treatment landscape of mCSPC. We aimed to compare the cost-effectiveness of abiraterone, enzalutamide, and apalutamide in addition to ADT in treating mCSPC from the US payer perspective. (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: A. Katta, R.N. Hansen Source Type: research
Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial
Prostate Cancer and Prostatic Diseases, Published online: 30 May 2023; doi:10.1038/s41391-023-00682-2Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - May 30, 2023 Category: Urology & Nephrology Authors: Carsten-Henning Ohlmann Michelle J äschke Peter Jaehnig Susanne Krege J ürgen Gschwend Heidrun Rexer Kerstin Junker Roger Zillmann Christoph R üssel Eva Hellmis Henrik Suttmann Martin Janssen Jan Marin Andreas H übner Michael Mathers Jochen Glei ßner Source Type: research
Association between RCT methodology and disease indication with mineralocorticoid-related toxicity for patients receiving abiraterone acetate for advanced prostate cancer: A meta-analysis of RCTs
CONCLUSIONS: The magnitude of cardiotoxicity with AA differs based on trial design and disease indication. These data are valuable in treatment decisions and highlight utilization of appropriate data for counseling.PMID:37236862 | DOI:10.1016/j.clgc.2023.04.007 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - May 26, 2023 Category: Cancer & Oncology Authors: Mary E Hall Whitney J Padgett Zachary Klaassen Diana E Magee Amy N Luckenbaugh Aaron A Laviana Raj Satkunasivam Kerry Schaffer Christopher J D Wallis Source Type: research
Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)-A Potential New Standard of Care
Curr Oncol. 2023 Apr 20;30(4):4365-4378. doi: 10.3390/curroncol30040332.ABSTRACTThe treatment paradigm for metastatic castrate-sensitive prostate cancer (mCSPC) has evolved rapidly in the past decade with the approval of several life-prolonging therapies including docetaxel chemotherapy and multiple androgen receptor pathway inhibitors (ARPI) in combination with androgen deprivation therapy (ADT). Recently reported phase-three trials have demonstrated a survival benefit of upfront triplet therapy with ADT, docetaxel plus either abiraterone acetate or darolutamide when compared to ADT plus docetaxel alone. However, multiple...
Source: Current Oncology - May 15, 2023 Category: Cancer & Oncology Authors: Abhenil Mittal Srikala S Sridhar Michael Ong Di Maria Jiang Source Type: research
Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)-A Potential New Standard of Care
Curr Oncol. 2023 Apr 20;30(4):4365-4378. doi: 10.3390/curroncol30040332.ABSTRACTThe treatment paradigm for metastatic castrate-sensitive prostate cancer (mCSPC) has evolved rapidly in the past decade with the approval of several life-prolonging therapies including docetaxel chemotherapy and multiple androgen receptor pathway inhibitors (ARPI) in combination with androgen deprivation therapy (ADT). Recently reported phase-three trials have demonstrated a survival benefit of upfront triplet therapy with ADT, docetaxel plus either abiraterone acetate or darolutamide when compared to ADT plus docetaxel alone. However, multiple...
Source: Current Oncology - May 15, 2023 Category: Cancer & Oncology Authors: Abhenil Mittal Srikala S Sridhar Michael Ong Di Maria Jiang Source Type: research
Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
Eur Urol Open Sci. 2023 Apr 29;52:40-43. doi: 10.1016/j.euros.2023.03.009. eCollection 2023 Jun.ABSTRACTThe PROpel trial assessed the combination of olaparib + abiraterone acetate (AA) plus prednisone and androgen deprivation therapy (ADT) versus AA plus prednisone and ADT alone as first-line treatment for metastatic castration-resistant prostate cancer (mCPRP). To contextualize the progression free survival (PFS) benefit in PROpel, we performed a systematic review and quasi-individual patient data network meta-analysis on randomized controlled trials of first-line hormonal treatments for mCPRC. Meta-analysis was performed...
Source: Cancer Control - May 14, 2023 Category: Cancer & Oncology Authors: Giuseppe Fallara Daniele Robesti Daniele Raggi Francesco Montorsi Andrea Necchi Matthew R Cooperberg Bernard Malavaud Guillaume Ploussard Alberto Martini Source Type: research
New European approval: Fixed dose association of niraparib and abiraterone acetate in metastatic castration resistant prostate cancer with BRCA1/2 mutation
Bull Cancer. 2023 May 12:S0007-4551(23)00213-8. doi: 10.1016/j.bulcan.2023.04.018. Online ahead of print.NO ABSTRACTPMID:37183059 | DOI:10.1016/j.bulcan.2023.04.018 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 14, 2023 Category: Cancer & Oncology Authors: Herv é Bischoff Philippe Barth élémy Source Type: research
New European approval: Fixed dose association of niraparib and abiraterone acetate in metastatic castration resistant prostate cancer with BRCA1/2 mutation
Bull Cancer. 2023 May 12:S0007-4551(23)00213-8. doi: 10.1016/j.bulcan.2023.04.018. Online ahead of print.NO ABSTRACTPMID:37183059 | DOI:10.1016/j.bulcan.2023.04.018 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 14, 2023 Category: Cancer & Oncology Authors: Herv é Bischoff Philippe Barth élémy Source Type: research
New European approval: Fixed dose association of niraparib and abiraterone acetate in metastatic castration resistant prostate cancer with BRCA1/2 mutation
Bull Cancer. 2023 May 12:S0007-4551(23)00213-8. doi: 10.1016/j.bulcan.2023.04.018. Online ahead of print.NO ABSTRACTPMID:37183059 | DOI:10.1016/j.bulcan.2023.04.018 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 14, 2023 Category: Cancer & Oncology Authors: Herv é Bischoff Philippe Barth élémy Source Type: research
